Arie Belldegrun and David Chang godfather the $110M launch of a new cell therapy player. And this one is also thinking big
Back in 2015, when Arie Belldegrun and David Chang were running the show at Kite as the biotech raced to a historic approval for a CAR-T therapy, they picked up a small outfit called the T-Cell Factory in Amsterdam for the modest sum of $21 million.
The company — which they would use to set up shop in the EU — had been working under the guidance of Ton N. M. Schumacher, a top scientist at the Netherlands Cancer Institute who offered the cell therapy gurus at Kite an intriguing window on TCR research.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.